<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Guaifenesin and phenylephrine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Guaifenesin and phenylephrine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Guaifenesin and phenylephrine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8750" href="/d/html/8750.html" rel="external">see "Guaifenesin and phenylephrine: Drug information"</a> and <a class="drug drug_patient" data-topicid="12523" href="/d/html/12523.html" rel="external">see "Guaifenesin and phenylephrine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F177771"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Chest Congestion Relief PE [OTC];</li>
<li>Deconex IR [OTC];</li>
<li>ED Bron GP [OTC];</li>
<li>Fenesin PE IR [OTC] [DSC];</li>
<li>FT Chest Congestion Relief PE [OTC];</li>
<li>Gcon IR [OTC];</li>
<li>Maxi-Tuss PE Jr [OTC];</li>
<li>Maxi-Tuss PE Max [OTC];</li>
<li>Mucinex Stuffy Nose &amp; Chest [OTC];</li>
<li>Mucinex Stuffy Nose/Cold Child [OTC] [DSC];</li>
<li>MucusRelief Sinus [OTC] [DSC];</li>
<li>Pharbinex-PE [OTC];</li>
<li>Refenesen PE [OTC];</li>
<li>Triaminic Chest/Nasal Congest [OTC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1017092"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Decongestant</span>;</li>
<li>
<span class="list-set-name">Expectorant</span></li></ul></div>
<div class="block dop drugH1Div" id="F177781"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Safety and efficacy for the use of cough and cold products in infants and young children are limited; the AAP warns against the use of these products for respiratory illnesses in infants and young children; the FDA does not recommend OTC use in infants and children &lt;2 years of age due to the risk of serious and life-threatening adverse effects (including death) and recommends using with caution in pediatric patients ≥2 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1','lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1','lexi-content-ref-FDA.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="875949dd-7463-42f6-9e91-fd1d7f5c3bcb">Cold, allergy symptoms</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cold, allergy symptoms: Note:</b> Multiple formulations of tablet strength and oral liquid concentrations exist; pay close attention to the concentration/strength when ordering or administering.</p>
<p style="text-indent:-2em;margin-left:4em;">Liquid:</p>
<p style="text-indent:-2em;margin-left:6em;">Guaifenesin 50 mg and phenylephrine 2.5 mg per 5 mL (eg, Maxi-Tuss PE Jr):</p>
<p style="text-indent:-2em;margin-left:8em;">Children 6 to &lt;12 years: Oral: 10 mL every 4 hours as needed; maximum daily dose: 60 mL per <b>24 hours</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥12 years and Adolescents: Oral: 20 mL every 4 hours as needed; maximum daily dose: 120 mL per <b>24 hours</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">Guaifenesin 100 mg and phenylephrine 2.5 mg per 5 mL (eg, Mucinex Children's Stuffy Nose and Chest Congestion):</p>
<p style="text-indent:-2em;margin-left:8em;">Children 4 to &lt;6 years: Oral: 5 mL every 4 hours as needed; maximum daily dose: 30 mL per <b>24 hours</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">Children 6 to &lt;12 years: Oral: 10 mL every 4 hours as needed; maximum daily dose: 60 mL per <b>24 hours</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">Guaifenesin 100 mg and phenylephrine 5 mg per 5 mL (eg, Ed Bron GP, Maxi-Tuss PE Max):</p>
<p style="text-indent:-2em;margin-left:8em;">Children 6 to &lt;12 years: Oral: 5 mL every 4 hours as needed; maximum daily dose: 30 mL per <b>24 hours</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥12 years and Adolescents: Oral: 10 mL every 4 hours as needed; maximum daily dose: 60 mL per <b>24 hours</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet:</p>
<p style="text-indent:-2em;margin-left:6em;">Guaifenesin 385 mg and phenylephrine 10 mg per tablet (eg, Deconex IR):</p>
<p style="text-indent:-2em;margin-left:8em;">Children 6 to &lt;12 years: Oral: <sup>1</sup>/<sub>2</sub> tablet every 4 hours as needed; maximum daily dose: 3 tablets per <b>24 hours</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥12 years and Adolescents: Oral: 1 tablet every 4 hours as needed; maximum daily dose: 6 tablets per <b>24 hours</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">Guaifenesin 400 mg and phenylephrine 10 mg per tablet (eg, Chest Congestion Relief PE):</p>
<p style="text-indent:-2em;margin-left:8em;">Children 6 years to &lt;12 years: Oral: <sup>1</sup>/<sub>2</sub> tablet every 4 hours as needed; maximum daily dose: 3 tablets per <b>24 hours</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥12 years and Adolescents: Oral: 1 tablet every 4 hours as needed; maximum daily dose: 6 tablets per <b>24 hours</b>.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F57662463"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F57662464"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F177774"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8750" href="/d/html/8750.html" rel="external">see "Guaifenesin and phenylephrine: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a4d8d584-ffb3-450f-adf3-db72cfcc649f">Expectorant/decongestant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Expectorant/decongestant:</b> Dosing may vary by product; consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">Liquid: <b>Oral: </b></p>
<p style="text-indent:-2em;margin-left:6em;">Guaifenesin 50 mg/phenylephrine 2.5 mg per 5 mL: 20 mL every 4 hour; maximum: 120 mL per 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Guaifenesin 100 mg/phenylephrine 5 mg per 5 mL: 10 mL every 4 hours; maximum: 60 mL per 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet: <b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Guaifenesin 385 mg/phenylephrine 10 mg per tablet: One tablet every 4 hours; maximum: 6 tablets per 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Guaifenesin 400 mg/phenylephrine 10 mg per tablet: One tablet every 4 hours; maximum: 6 tablets per 24 hours.</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F177756"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">See individual agents.</p></div>
<div class="block coi drugH1Div" id="F177765"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Concurrent administration with or within 2 weeks of discontinuing an MAO inhibitor.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F177753"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease); contraindicated with severe disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes mellitus.</p>
<p style="text-indent:-2em;margin-left:4em;">• Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or glaucoma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in the elderly; may be more sensitive to adverse effects.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggest that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP ["Inactive" 1997]; Zar 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cough: Appropriate use: Underlying cause of cough should be determined prior to prescribing.</p>
<p style="text-indent:-2em;margin-left:4em;">• Self-medication (OTC use): When used for self-medication (OTC), do not exceed recommended doses; discontinue use and contact health care provider if symptoms do not improve within 7 days or are accompanied by fever, rash, persistent headache, or excessive mucus; if nervousness, dizziness, or sleeplessness occur; or if new symptoms occur.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52950601"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Safety and efficacy for the use of cough and cold products in pediatric patients &lt;4 years of age is limited; the AAP warns against the use of these products for respiratory illnesses in young children. Serious adverse effects including death have been reported (in some cases, high blood concentrations of pseudoephedrine were found). Many of these products contain multiple active ingredients, increasing the risk of accidental overdose when used with other products. The FDA does not recommend OTC uses for these products in pediatric patients &lt;2 years of age, and recommends to use with caution in pediatric patients ≥2 years of age. Health care providers are reminded to ask caregivers about the use of OTC cough and cold products in order to avoid exposure to multiple medications containing the same ingredient (AAP 2018; CDC 2007; FDA 2017; FDA 2018). Multiple concentrations of oral liquid formulations exist; close attention must be paid to the concentration when ordering or administering.</p>
<p style="text-indent:0em;margin-top:2em;">Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F177760"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Liquid, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ED Bron GP: Guaifenesin 100 mg and phenylephrine hydrochloride 5 mg per 5 mL (473 mL) [alcohol free, dye free, sugar free; contains methylparaben, propylene glycol, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Maxi-Tuss PE Jr: Guaifenesin 50 mg and phenylephrine hydrochloride 2.5 mg per 5 mL (473 mL) [alcohol free, dye free, sugar free; contains methylparaben, propylene glycol, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Maxi-Tuss PE Max: Guaifenesin 100 mg and phenylephrine hydrochloride 5 mg per 5 mL (473 mL) [alcohol free, dye free, sugar free; contains methylparaben, propylene glycol, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mucinex Stuffy Nose &amp; Chest: Guaifenesin 100 mg and phenylephrine hydrochloride 2.5 mg per 5 mL (118 mL) [contains edetate (edta) disodium, fd&amp;c red #40 (allura red ac dye), glycerin (soy), propylene glycol, sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mucinex Stuffy Nose/Cold Child: Guaifenesin 100 mg and phenylephrine hydrochloride 2.5 mg per 5 mL (118 mL [DSC]) [contains edetate (edta) disodium, fd&amp;c red #40 (allura red ac dye), propylene glycol, sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Triaminic Chest/Nasal Congest: Guaifenesin 50 mg and phenylephrine hydrochloride 2.5 mg per 5 mL (118 mL) [contains benzoic acid, fd&amp;c yellow #6 (sunset yellow), propylene glycol, quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Chest Congestion Relief PE: Guaifenesin 400 mg and phenylephrine hydrochloride 10 mg [dye free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Deconex IR: Guaifenesin 385 mg and phenylephrine hydrochloride 10 mg [scored; contains fd&amp;c blue #1 (brilliant blue), fd&amp;c yellow #5 (tartrazine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fenesin PE IR: Guaifenesin 400 mg and phenylephrine hydrochloride 10 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT Chest Congestion Relief PE: Guaifenesin 400 mg and phenylephrine hydrochloride 10 mg [scored; dye free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gcon IR: Guaifenesin 385 mg and phenylephrine hydrochloride 10 mg [scored; contains fd&amp;c blue #1 (brilliant blue), fd&amp;c yellow #5 (tartrazine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">MucusRelief Sinus: Guaifenesin 400 mg and phenylephrine hydrochloride 10 mg [DSC] [pseudoephedrine free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pharbinex-PE: Guaifenesin 400 mg and phenylephrine hydrochloride 10 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Refenesen PE: Guaifenesin 400 mg and phenylephrine hydrochloride 10 mg [scored; dye free, pseudoephedrine free]</p></div>
<div class="block geq drugH1Div" id="F177749"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F177766"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Liquid</b> (Mucinex Stuffy Nose &amp; Chest Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5-100 mg/5 mL (per mL): $0.09</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Liquid</b> (Supress-PE Pediatric Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5-50 mg/mL (per mL): $0.45</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Liquid</b> (Triaminic Chest/Nasal Congest Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5-50 mg/5 mL (per mL): $0.04</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Liquid</b> (Tusnel Pediatric Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.25-25 mg/mL (per mL): $0.30</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Liquid</b> (Tussi-Pres PE Pediatric Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5-100 mg/5 mL (per mL): $0.07</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Deconex IR Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10-385 mg (per each): $0.76</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Giltuss Sinus &amp; Congestion Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10-388 mg (per each): $0.45</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52612951"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral:</p>
<p style="text-indent:-2em;margin-left:2em;">Liquid: Administer liquid formulations with an accurate measuring device; do not use a household teaspoon (overdosage may occur).</p></div>
<div class="block sts drugH1Div" id="F54480839"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;">Store at 15°C to 30°C (59°F to 86°F).</p></div>
<div class="block usep drugH1Div" id="F53567162"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Temporary relief of the symptoms associated with the common cold, hay fever, or other respiratory allergies. <b>Note:</b> Approved ages and uses for products may vary; consult labeling for specific information.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Liquid:</p>
<p style="text-indent:-2em;margin-left:6em;">Guaifenesin 50 mg and phenylephrine 2.5 mg per 5 mL (eg, Maxi-Tuss PE Jr): OTC product: FDA approved in ages ≥6 years and adults.</p>
<p style="text-indent:-2em;margin-left:6em;">Guaifenesin 100 mg and phenylephrine 5 mg per 5 mL (eg, Ed Bron GP, Maxi-Tuss PE Max): OTC product: FDA approved in ages ≥6 years and adults.</p>
<p style="text-indent:-2em;margin-left:6em;">Guaifenesin 100 mg and phenylephrine 2.5 mg per 5 mL (eg, Mucinex Children's Stuffy Nose and Chest Congestion): OTC product: FDA approved in ages ≥4 to &lt;12 years.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablets:</p>
<p style="text-indent:-2em;margin-left:6em;">Guaifenesin 385 mg and phenylephrine 10 mg per tablet (eg, Deconex IR): OTC product: FDA approved in ages ≥6 years and adults.</p>
<p style="text-indent:-2em;margin-left:6em;">Guaifenesin 400 mg and phenylephrine 10 mg per tablet (eg, Chest Congestion Relief PE): OTC product: FDA approved in ages ≥6 years and adults.</p></div>
<div class="block mst drugH1Div" id="F177791"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Entex may be confused with Tenex</p>
<p style="text-indent:-2em;margin-left:4em;">Entex LA brand name represents a different product in the US than it does in Canada. Formerly available in the US, Entex LA contains guaifenesin and phenylephrine, while in Canada the product bearing this brand name contains guaifenesin and pseudoephedrine.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299426"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F177757"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetaminophen: May increase the serum concentration of Phenylephrine (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: May enhance the hypertensive effect of Sympathomimetics. Atomoxetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atropine (Systemic): May enhance the hypertensive effect of Alpha1-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzylpenicilloyl Polylysine: Alpha1-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider delaying skin testing until alpha1-agonists are no longer required, or use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromocriptine: May enhance the hypertensive effect of Alpha1-Agonists. Management: Consider alternatives to this combination when possible. If combined, monitor for hypertension and tachycardia, and do not coadminister these agents for more than 10 days.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloroprocaine (Systemic): May enhance the hypotensive effect of Phenylephrine (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: May diminish the therapeutic effect of Phenylephrine (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disulfiram: May enhance the adverse/toxic effect of Products Containing Ethanol. Management: Do not use disulfiram with dosage forms that contain ethanol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): May enhance the vasoconstricting effect of Alpha1-Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">FentaNYL: Decongestants may decrease the serum concentration of FentaNYL. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: May enhance the vasoconstricting effect of Phenylephrine (Systemic). Management: Do not use hyaluronidase to enhance the dispersion or absorption of phenylephrine. Use of hyaluronidase for other purposes in patients receiving phenylephrine may be considered as clinically indicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iobenguane Radiopharmaceutical Products: Alpha1-Agonists may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products.  Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the adverse/toxic effect of Sympathomimetics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: May enhance the adverse/toxic effect of Sympathomimetics. Specifically, the risk of coronary insufficiency may be increased in patients with coronary artery disease. Levothyroxine may enhance the therapeutic effect of Sympathomimetics. Sympathomimetics may enhance the therapeutic effect of Levothyroxine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Consider initial dose reductions of sympathomimetic agents, and closely monitor for enhanced blood pressure elevations, in patients receiving linezolid.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the hypertensive effect of Alpha1-Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: Products Containing Ethanol may enhance the adverse/toxic effect of Methotrimeprazine. Specifically, a disulfiram-like reaction may occur and CNS depressant effects may be increased.  Management: Avoid products containing alcohol in patients treated with methotrimeprazine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists. While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.  Refer to linezolid specific monographs for details.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ornidazole: May enhance the adverse/toxic effect of Products Containing Ethanol. Specifically, a disulfiram-like reaction may occur.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pergolide: May enhance the hypertensive effect of Alpha1-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propacetamol: May increase the serum concentration of Phenylephrine (Systemic). Management: Monitor patients closely for increased side effects of phenylephrine if propacetamol is used concomitantly. Patients with underlying blood pressure issues or arrhythmias may need closer monitoring and may warrant consideration of alternative therapies.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secnidazole: Products Containing Ethanol may enhance the adverse/toxic effect of Secnidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May enhance the therapeutic effect of Alpha1-Agonists. Tricyclic Antidepressants may diminish the therapeutic effect of Alpha1-Agonists.<i> Risk C: Monitor therapy</i></p></div>
<div class="block dic drugH1Div" id="F177769"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">May be taken with or without food. Taking with food, water or milk may help decrease gastric irritation. Some products may contain sodium.</p></div>
<div class="block pri drugH1Div" id="F177767"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Refer to individual monographs.</p></div>
<div class="block pha drugH1Div" id="F177752"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">See individual agents.</p></div>
<div class="block phk drugH1Div" id="F177764"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">See individual agents.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F52158767"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Benadryl pe chesty cough &amp; nasal congestion | Codral mucus cough + cold | Codral relief mucus cough &amp; cold | Robitussin chesty cough &amp; nasal congestion PE | Robitussin cold &amp; chesty cough</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Codral relief mucus cough &amp; cold</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Albatussin pe | Crantex la | Duravent pe | Ed bron gp | Endal | Entex lq | Fenesin pe ir | Gentex LA | Gfn/Pe | Gilphex tr | Giltuss sinus &amp; congestion | Guaiphen-pd | Liquibid D | Liquibid D R | Liquibid PD R | Maxi tuss pe jr | Maxi tuss pe max | Medent pei | Mucaphed | Mucus relief sinus | Mydocs | Nu copd | Numonyl | Pharbinex pe | Phenavent d | Phenavent la | Proset d | Relcof ir | Reluri | Rescon-gg | Respa PE | Simuc | Sina-12x | Sudex | Triaminic chest &amp; nasal congestion | Visonex | Xedec II</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guaifenesin-and-phenylephrine-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). Cough and cold medicines should not be prescribed, recommended or used for respiratory illnesses in young children. Updated June 12, 2018. http://www.choosingwisely.org/clinician-lists/american-academy-pediatrics-cough-and-cold-medicines-for-children-under-four/
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.2">
<a name="AAP.2"></a>American Academy of Pediatrics (AAP). Five things physicians and patients should question. April 4, 2012. http://www.choosingwisely.org/choosing-wisely-five-things-physicians-and-patients-should-question-press-release-april-4-2012/
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guaifenesin-and-phenylephrine-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17218934">
<a name="17218934"></a>Centers for Disease Control and Prevention (CDC). Infant deaths associated with cough and cold medications--two states, 2005. <i>MMWR Morb Mortal Wkly Rep</i>. 2007;56(1):1-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guaifenesin-and-phenylephrine-pediatric-drug-information/abstract-text/17218934/pubmed" id="17218934" target="_blank">17218934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291.<a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guaifenesin-and-phenylephrine-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Chest Congestion Relief PE (guaifenesin and phenylephrine) [prescribing information]. Livonia, MI: Rugby Laboratories; July 2020.</div>
</li>
<li>
<div class="reference">
                  Children's Mucinex Stuffy Nose &amp; Cold solution (guaifenesin and phenylephrine) [prescribing information]. Parsippany, NJ: Reckitt Benckiser; September 2016.</div>
</li>
<li>
<div class="reference">
                  Deconex IR (guaifenesin and phenylephrine) [prescribing information]. Huntsville, AL: Poly Pharmaceuticals; June 2016.</div>
</li>
<li>
<div class="reference">
                  Duravent (guaifenesin and phenylephrine) [prescribing information]. Canton, MS: Allegis Pharmaceuticals; February 2014.</div>
</li>
<li>
<div class="reference">
                  Ed Bron GP liquid (guaifenesin and phenylephrine) [prescribing information]. Ripley, MS: Edwards Pharmaceuticals; June 2022.</div>
</li>
<li>
<div class="reference">
                  Ed Bron GP liquid (guaifenesin and phenylephrine) [prescribing information]. Ripley, MS: Edwards Pharmaceuticals; March 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>Food and Drug Administration (FDA). Most young children with a cough or cold don't need medicines. July 18, 2017. <a href="https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm422465.htm" target="_blank">https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm422465.htm</a>. Last accessed November 2, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2">
<a name="FDA.2"></a>Food and Drug Administration (FDA). Use caution when giving cough and cold products to kids. Updated February 8, 2018. <a href="https://www.fda.gov/drugs/resourcesforyou/specialfeatures/ucm263948.htm" target="_blank">https://www.fda.gov/drugs/resourcesforyou/specialfeatures/ucm263948.htm</a>. Last accessed November 2, 2018.</div>
</li>
<li>
<div class="reference">
                  Maxi-Tuss PE Jr (guaifenesin and phenylephrine) [prescribing information]. Brooksville, FL: MCR American Pharmaceuticals Inc; May 2020.</div>
</li>
<li>
<div class="reference">
                  Maxi-Tuss PE Max (guaifenesin and phenylephrine) [prescribing information]. Brooksville, FL: MCR American Pharmaceuticals Inc; May 2020.</div>
</li>
<li>
<div class="reference">
                  Mucinex Children's Stuffy Nose and Chest (guaifenesin and phenylephrine) [prescribing information]. Parsippany, NJ: RB Health (US); received November 2020.</div>
</li>
<li>
<div class="reference">
                  Mucus Relief D Immediate Release (guaifenesin and phenylephrine) [prescribing information]. Deer Park, NY: Allegiant Health; December 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guaifenesin-and-phenylephrine-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17253470">
<a name="17253470"></a>Taverner D, Latte J. Nasal decongestants for the common cold. <i>Cochrane Database Syst Rev</i>. 2007;(1):CD001953.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guaifenesin-and-phenylephrine-pediatric-drug-information/abstract-text/17253470/pubmed" id="17253470" target="_blank">17253470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guaifenesin-and-phenylephrine-pediatric-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 120977 Version 109.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
